ReviewJournal of diabetes and metabolic disorders2018
Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy.
Review in Journal of diabetes and metabolic disorders, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.
- The prognostic role of circulating DNA markers in patients with lung malignancies: a systematic review and meta-analysis.Biomarkers in medicine · 2025Pooled it
- Assessing circulating tumour DNA (ctDNA) as a prognostic biomarker in locally advanced rectal cancer: a systematic review and meta-analysis.International journal of colorectal disease · 2024Pooled it
- Individualized circulating tumor DNA monitoring in two dogs with malignant melanoma.The Journal of veterinary medical science · 2026Article
- Clinical Validation of Digital PCR-Based ctDNA Detection for Risk Stratification in Residual Triple-Negative Breast Cancer: TRICIA Trial Results.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Transforming Cancer Care: Genomic Profiling, AI, and Next-Generation Drug Delivery Systems.Current genomics · 2025Review
- Thyroid Cancer research at endocrinology and metabolism research institute (EMRI): a report of scientific activities between 2005 and 2020.Journal of diabetes and metabolic disorders · 2024Review
- Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance.Molecular cancer · 2023Review
- Liquid biopsies and minimal residual disease in myeloid malignancies.Frontiers in oncology · 2023Review
- KMT2D promotes proliferation of gastric cancer cells: evidence from ctDNA sequencing.Journal of clinical laboratory analysis · 2021Article
- Evaluation of the Possibility to Detect Circulating Tumor DNA From Pituitary Adenoma.Frontiers in endocrinology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The heterogeneity of tumor is considered as a major difficulty to victorious personalized cancer medicine. There is an extremeneed of consistent response evaluation for in vivo tumor heterogeneity anditscoupledconflict mechanisms. In this occasion researchers will be able to keep pace withpredictive, preventive, personalized, and Participatory (P4) medicine for cancer managements. In fact tumor heterogeneity is a central part of cancer evolution,soin order to progress in understanding of the dynamics within a tumor some diagnostic apparatus should be improved. Latest molecular techniques like Next generation Sequencing (NGS) and ultra-deep sequencing could disclose some clones within a liquid tumor biopsy which mainly responsible of treatment resistance. Circulating tumor DNA (ctDNA) as a main component of liquid biopsy is agifted biomarker for cancer mutation tracking as well as profiling. Personalized medicine facilitate learning regarding to genetic pools of tumor and their possible respond to treatment which could be much easier by using of ctDNA.With this information, cliniciansarelooking forward to find the best strategies for prevention, screening, and treatment in the way of precision medicine. Currently, numerous clinical efficacy of such informative improved treatment are in hand. Here we represent the review of plasma-derived ctDNA studies use in personalized cancer managements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.